Published in J Natl Cancer Inst on April 16, 2003
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer | NCT00436215
BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors | NCT00095459
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A (2005) 8.60
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A (2009) 6.78
Integrated genomic characterization of papillary thyroid carcinoma. Cell (2014) 6.05
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol (2008) 5.31
Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A (2008) 5.29
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer (2013) 4.46
BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut (2004) 4.06
Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol (2009) 3.73
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med (2013) 3.21
Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 3.09
BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol (2009) 3.02
Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog (2004) 3.02
Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol (2011) 2.96
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci U S A (2005) 2.93
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest (2005) 2.77
Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol (2008) 2.58
Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest (2008) 2.17
Retracted The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest (2005) 2.09
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res (2012) 2.02
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab (2008) 1.95
Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn (2007) 1.85
Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol (2006) 1.66
Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch (2005) 1.62
Existing and emerging technologies for tumor genomic profiling. J Clin Oncol (2013) 1.52
Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer (2005) 1.39
The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One (2012) 1.34
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res (2007) 1.33
Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab (2008) 1.31
The MAPK pathway across different malignancies: a new perspective. Cancer (2014) 1.22
Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Hum Genet (2003) 1.21
Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. Am J Pathol (2005) 1.18
Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas. Curr Genomics (2011) 1.18
MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity. Eye (Lond) (2015) 1.18
B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol (2013) 1.14
BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab (2007) 1.12
Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg (2006) 1.09
Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int J Endocrinol (2014) 1.07
Absence of a specific radiation signature in post-Chernobyl thyroid cancers. Br J Cancer (2005) 1.07
Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal (2006) 1.06
Oncogenic activation of MAP kinase by BRAF pseudogene in thyroid tumors. Neoplasia (2009) 1.06
Mechanisms of chromosomal rearrangements in solid tumors: the model of papillary thyroid carcinoma. Mol Cell Endocrinol (2009) 1.06
Translocations in epithelial cancers. Biochim Biophys Acta (2009) 1.04
MEK genomics in development and disease. Brief Funct Genomics (2012) 1.04
DMSO and betaine greatly improve amplification of GC-rich constructs in de novo synthesis. PLoS One (2010) 1.02
Loss of Rap1GAP in papillary thyroid cancer. J Clin Endocrinol Metab (2008) 1.02
Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. ACS Med Chem Lett (2013) 1.00
Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. Virchows Arch (2004) 1.00
Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. J Mol Diagn (2006) 0.99
Diagnosis and treatment of patients with thyroid cancer. Am Health Drug Benefits (2015) 0.98
Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR. Biomark Res (2013) 0.98
BRAFV600E mutation and papillary thyroid cancer: chicken or egg? J Clin Endocrinol Metab (2012) 0.95
Animal models of cancer in the head and neck region. Clin Exp Otorhinolaryngol (2009) 0.95
BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch (2004) 0.95
Important molecular genetic markers of colorectal cancer. Oncotarget (2016) 0.94
Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in papillary thyroid carcinoma. PLoS One (2011) 0.93
BRAF inhibitors in clinical oncology. F1000Prime Rep (2013) 0.93
Molecular approaches to thyroid cancer diagnosis. Endocr Relat Cancer (2014) 0.93
BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Oncotarget (2016) 0.93
BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget (2014) 0.92
Clinicopathological and molecular histochemical review of skull base metastasis from differentiated thyroid carcinoma. Acta Histochem Cytochem (2013) 0.92
Morphologic characteristics of Chernobyl-related childhood papillary thyroid carcinomas are independent of radiation exposure but vary with iodine intake. Thyroid (2008) 0.92
Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma. Clin Cancer Res (2013) 0.92
What is New on Thyroid Cancer Biomarkers. Biomark Insights (2008) 0.91
Thyroid cancer: pathogenesis and targeted therapy. Ther Adv Endocrinol Metab (2011) 0.91
Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des Devel Ther (2014) 0.91
Correlation between BRAF mutation and promoter methylation of TIMP3, RARβ2 and RASSF1A in thyroid cancer. Epigenetics (2012) 0.90
Solitary liver metastasis from follicular variant papillary thyroid carcinoma: A case report and literature review. Int J Surg Case Rep (2014) 0.90
Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch (2005) 0.90
A gene expression signature distinguishes normal tissues of sporadic and radiation-induced papillary thyroid carcinomas. Br J Cancer (2012) 0.90
Detection of BRAF(V600E) Mutations in Papillary Thyroid Carcinomas by Peptide Nucleic Acid Clamp Real-Time PCR: A Comparison with Direct Sequencing. Korean J Pathol (2012) 0.89
The Frequency and Clinical Implications of the BRAF(V600E) Mutation in Papillary Thyroid Cancer Patients in Korea Over the Past Two Decades. Endocrinol Metab (Seoul) (2014) 0.89
Differential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanisms. Mol Cell Biol (2006) 0.89
Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. Thyroid (2014) 0.89
Aberrantly methylated genes in human papillary thyroid cancer and their association with BRAF/RAS mutation. Front Genet (2013) 0.89
Genetics of papillary thyroid cancer initiation: implications for therapy. Trans Am Clin Climatol Assoc (2005) 0.88
RAF kinase inhibitor-independent constitutive activation of Yes-associated protein 1 promotes tumor progression in thyroid cancer. Oncogenesis (2013) 0.87
Thyroid cancer: current molecular perspectives. J Oncol (2010) 0.87
Inflammation in thyroid oncogenesis. Am J Cancer Res (2012) 0.87
RET fusion as a novel driver of medullary thyroid carcinoma. J Clin Endocrinol Metab (2014) 0.87
Detection of BRAF mutation in Chinese tumor patients using a highly sensitive antibody immunohistochemistry assay. Sci Rep (2015) 0.87
Diagnostic and prognostic markers in differentiated thyroid cancer. Curr Genomics (2011) 0.86
Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. Oncologist (2015) 0.86
Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patients. Oncol Lett (2010) 0.85
Identification of a rare 3 bp BRAF gene deletion in a thyroid nodule by mutant enrichment with 3'-modified oligonucleotides polymerase chain reaction. Ann Lab Med (2012) 0.85
Selectively targeting mutant BRAF in thyroid cancer. J Clin Endocrinol Metab (2010) 0.85
Genetics and epigenetics of sporadic thyroid cancer. Mol Cell Endocrinol (2013) 0.85
Pax-8-PPAR-γ fusion protein in thyroid carcinoma. Nat Rev Endocrinol (2014) 0.85
High-resolution melting analysis for accurate detection of BRAF mutations: a systematic review and meta-analysis. Sci Rep (2014) 0.85
Genetic and epigenetic analysis of erbB signaling pathway genes in lung cancer. J Thorac Oncol (2010) 0.84
Functions of MiRNA-128 on the regulation of head and neck squamous cell carcinoma growth and apoptosis. PLoS One (2015) 0.84
Differential diagnosis of thyroid nodules using fine-needle aspiration cytology and oncogene mutation screening: are we ready? F1000 Med Rep (2010) 0.83
Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases. BMC Cancer (2005) 0.83
Association between single-nucleotide polymorphisms of BRAF and papillary thyroid carcinoma in a Chinese population. Thyroid (2013) 0.83
Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells. Am J Pathol (2012) 0.83
Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis. J Clin Pathol (2007) 0.83
Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst (2008) 12.77
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res (2002) 7.09
HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol (2010) 6.53
TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med (2007) 5.92
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med (2006) 5.80
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39
Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med (2005) 4.12
Thyroid status, cardiovascular risk, and mortality in older adults. JAMA (2006) 3.50
Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res (2003) 3.42
A model to determine workforce needs for endocrinologists in the United States until 2020. J Clin Endocrinol Metab (2003) 3.38
Hypothyroidism. Lancet (2004) 3.26
Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell (2002) 3.12
Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol (2012) 3.04
Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid (2006) 3.03
Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab (2008) 2.89
Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res (2004) 2.84
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81
A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther (2011) 2.74
Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer (2013) 2.69
Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res (2008) 2.66
Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res (2007) 2.61
MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer (2008) 2.56
The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res (2004) 2.54
p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst (2003) 2.54
DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res (2003) 2.46
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
DNA methylation markers in colorectal cancer. Cancer Metastasis Rev (2010) 2.40
Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res (2004) 2.34
Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res (2005) 2.32
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31
Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J Mol Diagn (2013) 2.27
Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab (2003) 2.27
p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol (2011) 2.24
Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res (2005) 2.20
Aquaporin 1 is overexpressed in lung cancer and stimulates NIH-3T3 cell proliferation and anchorage-independent growth. Am J Pathol (2006) 2.19
Basaloid squamous cell carcinoma of the head and neck is a mixed variant that can be further resolved by HPV status. Am J Surg Pathol (2008) 2.10
A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res (2004) 2.06
The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway. J Clin Endocrinol Metab (2011) 2.06
Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst (2006) 2.05
The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle (2012) 1.98
Mitochondrial C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation. Clin Cancer Res (2002) 1.97
Cystic lymph node metastasis in patients with head and neck cancer: An HPV-associated phenomenon. Head Neck (2008) 1.97
Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid (2008) 1.93
Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab (2009) 1.93
Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res (2002) 1.88
Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol (2009) 1.88
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med (2006) 1.86
Oral human papillomavirus infection before and after treatment for human papillomavirus 16-positive and human papillomavirus 16-negative head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.85
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res (2011) 1.85
Patient-derived xenografts for individualized care in advanced sarcoma. Cancer (2014) 1.82
Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res (2010) 1.81
Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol (2005) 1.80
High-risk human papillomavirus in nasopharyngeal carcinoma. Head Neck (2011) 1.79
Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer. J Natl Cancer Inst (2013) 1.78
BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore) (2012) 1.77
Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res (2004) 1.76
Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res (2004) 1.74
Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med (2007) 1.73
Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl) (2006) 1.72
Tumor-specific changes in mtDNA content in human cancer. Int J Cancer (2005) 1.70
Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res (2008) 1.70
DITPA (3,5-Diiodothyropropionic Acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study. Circulation (2009) 1.70
Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol (2006) 1.69
A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid (2010) 1.68
Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci U S A (2007) 1.68
Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. Cancer Prev Res (Phila) (2010) 1.68
Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab (2007) 1.66